Cargando…

Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy

BACKGROUND: Fatigue and insomnia are common symptoms experienced by breast cancer patients undergoing adjuvant radiation therapy (RT), yet the underlying mechanisms of these symptoms are unclear. In particular, the roles of hematopoietic stem cells (HSCs) and inflammatory cytokines remain to be eluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wei, Misra, Shagun, Li, Madeline, Su, Jie, Chong, Lisa P, McCuske, Megan, Williams, Justin, Xu, Wei, Ghoraie, Laleh S, Sutherland, D Robert, Han, Kathy, Minden, Mark D, Bratman, Scott V, Yip, Kenneth W, Liu, Fei-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583146/
https://www.ncbi.nlm.nih.gov/pubmed/33134822
http://dx.doi.org/10.1093/jncics/pkaa037
_version_ 1783599341766705152
author Shi, Wei
Misra, Shagun
Li, Madeline
Su, Jie
Chong, Lisa P
McCuske, Megan
Williams, Justin
Xu, Wei
Ghoraie, Laleh S
Sutherland, D Robert
Han, Kathy
Minden, Mark D
Bratman, Scott V
Yip, Kenneth W
Liu, Fei-Fei
author_facet Shi, Wei
Misra, Shagun
Li, Madeline
Su, Jie
Chong, Lisa P
McCuske, Megan
Williams, Justin
Xu, Wei
Ghoraie, Laleh S
Sutherland, D Robert
Han, Kathy
Minden, Mark D
Bratman, Scott V
Yip, Kenneth W
Liu, Fei-Fei
author_sort Shi, Wei
collection PubMed
description BACKGROUND: Fatigue and insomnia are common symptoms experienced by breast cancer patients undergoing adjuvant radiation therapy (RT), yet the underlying mechanisms of these symptoms are unclear. In particular, the roles of hematopoietic stem cells (HSCs) and inflammatory cytokines remain to be elucidated. METHODS: Breast cancer patients (n = 147) completed questionnaires to longitudinally assess symptoms before, during, and after adjuvant RT. Phlebotomies were performed prior to RT, at the second and fifth treatment fractions, end of treatment (EOT), and 1 month after completing RT, assessing for CD34(+), CD45(+), full hematology, and 17 inflammatory cytokines. The associations between symptoms and all biomarkers were evaluated. All statistical tests were 2-sided. RESULTS: General fatigue and insomnia worsened with RT, with peak levels observed at EOT, which remained statistically significant even after controlling for anxiety and depression (P < .05 for all). CD34(+), CD45(+), white blood cell, and lymphocyte counts decreased, with the lowest levels also observed at EOT (P < .001). Fatigue and insomnia were associated with changes in both interferon γ-induced protein 10 (IP-10) - (P = .03 and P = .01, respectively) and tumor necrosis factor receptor II (TNF-RII) (P = .02 and P = .006, respectively), while mental fatigue was associated with increased matrix metalloproteinases-2 (MMP-2) levels (P = .03). Patients who received prior chemotherapy demonstrated statistically significantly greater severity in all symptoms, with lower baseline HSC levels. CONCLUSIONS: This is the first longitudinal study to examine linkages between symptoms, HSCs, and cytokines, demonstrating that fatigue and insomnia shared associations with increasing serum levels of IP-10 and TNF-RII, and mental fatigue was associated with increasing serum levels of MMP-2. Our findings highlight opportunities for further research into mechanisms and potential interventions for these symptoms.
format Online
Article
Text
id pubmed-7583146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75831462020-10-29 Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy Shi, Wei Misra, Shagun Li, Madeline Su, Jie Chong, Lisa P McCuske, Megan Williams, Justin Xu, Wei Ghoraie, Laleh S Sutherland, D Robert Han, Kathy Minden, Mark D Bratman, Scott V Yip, Kenneth W Liu, Fei-Fei JNCI Cancer Spectr Article BACKGROUND: Fatigue and insomnia are common symptoms experienced by breast cancer patients undergoing adjuvant radiation therapy (RT), yet the underlying mechanisms of these symptoms are unclear. In particular, the roles of hematopoietic stem cells (HSCs) and inflammatory cytokines remain to be elucidated. METHODS: Breast cancer patients (n = 147) completed questionnaires to longitudinally assess symptoms before, during, and after adjuvant RT. Phlebotomies were performed prior to RT, at the second and fifth treatment fractions, end of treatment (EOT), and 1 month after completing RT, assessing for CD34(+), CD45(+), full hematology, and 17 inflammatory cytokines. The associations between symptoms and all biomarkers were evaluated. All statistical tests were 2-sided. RESULTS: General fatigue and insomnia worsened with RT, with peak levels observed at EOT, which remained statistically significant even after controlling for anxiety and depression (P < .05 for all). CD34(+), CD45(+), white blood cell, and lymphocyte counts decreased, with the lowest levels also observed at EOT (P < .001). Fatigue and insomnia were associated with changes in both interferon γ-induced protein 10 (IP-10) - (P = .03 and P = .01, respectively) and tumor necrosis factor receptor II (TNF-RII) (P = .02 and P = .006, respectively), while mental fatigue was associated with increased matrix metalloproteinases-2 (MMP-2) levels (P = .03). Patients who received prior chemotherapy demonstrated statistically significantly greater severity in all symptoms, with lower baseline HSC levels. CONCLUSIONS: This is the first longitudinal study to examine linkages between symptoms, HSCs, and cytokines, demonstrating that fatigue and insomnia shared associations with increasing serum levels of IP-10 and TNF-RII, and mental fatigue was associated with increasing serum levels of MMP-2. Our findings highlight opportunities for further research into mechanisms and potential interventions for these symptoms. Oxford University Press 2020-05-08 /pmc/articles/PMC7583146/ /pubmed/33134822 http://dx.doi.org/10.1093/jncics/pkaa037 Text en © The Author(s) 2020. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Shi, Wei
Misra, Shagun
Li, Madeline
Su, Jie
Chong, Lisa P
McCuske, Megan
Williams, Justin
Xu, Wei
Ghoraie, Laleh S
Sutherland, D Robert
Han, Kathy
Minden, Mark D
Bratman, Scott V
Yip, Kenneth W
Liu, Fei-Fei
Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title_full Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title_fullStr Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title_full_unstemmed Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title_short Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy
title_sort inflammatory biomarkers, hematopoietic stem cells, and symptoms in breast cancer patients undergoing adjuvant radiation therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583146/
https://www.ncbi.nlm.nih.gov/pubmed/33134822
http://dx.doi.org/10.1093/jncics/pkaa037
work_keys_str_mv AT shiwei inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT misrashagun inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT limadeline inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT sujie inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT chonglisap inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT mccuskemegan inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT williamsjustin inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT xuwei inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT ghoraielalehs inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT sutherlanddrobert inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT hankathy inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT mindenmarkd inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT bratmanscottv inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT yipkennethw inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy
AT liufeifei inflammatorybiomarkershematopoieticstemcellsandsymptomsinbreastcancerpatientsundergoingadjuvantradiationtherapy